About this trial
Objective: To evaluate the safety and efficacy of transcatheter atrial fibrillation ablation 1 month after WATCHMAN FLX left atrial appendage closure in patients with nonvalvular atrial fibrillation.
Eligibility criteria
Qualifiers
≥18 years of age, diagnosed with nonvalvular atrial fibrillation;
Meet the indications for receiving WATCHMAN FLX left atrial appendicular closure and transcatheter atrial fibrillation ablation;
Preoperative imaging evaluation showed that the anatomical structure of the left atrial appendage was suitable for implantation with the WATCHMAN FLX device;
The patient agrees to participate in the study and signs the informed consent.
Disqualifiers
valvular heart disease or other structural heart disease that causes atrial fibrillation;
left auricular thrombus or acute thrombotic event was found before surgery;
Patients with severe bleeding tendency or recent major bleeding events (such as massive gastrointestinal bleeding, cerebral hemorrhage, etc.);
Patients who are unable to complete postoperative follow-up (such as life expectancy of less than 1 year or poor compliance);
Trial design
Treatments tested in this trial
- left atrial appendage closure
- radiofrequency ablation